Highlighted Text:
Show |
Hide
Full text loading...
Chapter 49 : Agents against Methicillin-Resistant Staphylococcus aureus
Author:
André Bryskier
Content Type: Reference
Publication Year:
2005
Category: Bacterial Pathogenesis
Book DOI:
10.1128/9781555815929
Chapter DOI:
10.1128/9781555815929.ch49
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Agents against Methicillin-Resistant Staphylococcus aureus, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap49-1.gif /docserver/preview/fulltext/10.1128/9781555815929/9781555812379_Chap49-2.gif
Abstract:
Infections due to methicillin-resistant Staphylococcus aureus (MRSA) are associated with a mortality rate of 15 to 60%. The first report of S. aureus resistant to penicillin occurred in 1942. A series of glycopeptides was prepared at Shionogi and displayed good in vitro anti-MRSA activity, with MICs ranging from 0.20 to 6.25 µg/ml. Daptomycin possesses an unusual amino acid, kynurenine. Modifications of this amino acid were attempted on the ketone and anilino groups. These modifications highlighted the importance of this amino acid for antibacterial activity. One of the most effective antibacterial strategies is to disrupt the integrity of bacterial cell wall formation. Peptidoglycan includes four steps in which amino acid residues are ligated to uridine-diphospho-N-acetylmuramic acid (UDP-MurNac). Benzylidene rhodamine is an inhibitor of MurC and is active against MRSA (MICs, 31 µM). A series of derivatives was synthesized, with the aim of improving logP and water solubility, as well as protein binding. Molecular iron is an essential factor for bacterial growth, iron being used during respiration, DNA replication, and other biological processes. One of the targets of a research was to improve water solubility, to obtain in vivo activity against MRSA, and to obtain both anti-MRSA activity and activity against gram-negative bacteria, including Pseudomonas aeruginosa. Deformylase is an essential bacterial metallo-enzyme responsible for the removal of the N-terminal formyl group from methionine following protein synthesis. Methionine aminopeptidases play a pivotal role in protein biosynthesis.
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
Figures
Agents against Methicillin-Resistant Staphylococcus aureus
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815929.ch49-1,webId=/content/author/10.1128/9781555815929.ch49-1,properties={foaf_givenname=André, foaf_name=André Bryskier, foaf_surname=Bryskier}]]
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig01
Figure 1
Prevalence of MRSA in Europe, 1999 to 2000
10.1128/9781555815929/f1183-01_thmb.gif
10.1128/9781555815929/f1183-01.gif
Figure 1
Prevalence of MRSA in Europe, 1999 to 2000
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig02
Figure 2
Cyclic peptoid
10.1128/9781555815929/f1185-01_thmb.gif
10.1128/9781555815929/f1185-01.gif
Figure 2
Cyclic peptoid
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig03
Figure 3
Lipidated vancomycin derivatives with disulfide bonds
10.1128/9781555815929/f1185-02_thmb.gif
10.1128/9781555815929/f1185-02.gif
Figure 3
Lipidated vancomycin derivatives with disulfide bonds
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig04
Figure 4
AC-98 complex
10.1128/9781555815929/f1187-01_thmb.gif
10.1128/9781555815929/f1187-01.gif
Figure 4
AC-98 complex
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig05
Figure 5
Nocathiacin(s)
10.1128/9781555815929/f1188-01_thmb.gif
10.1128/9781555815929/f1188-01.gif
Figure 5
Nocathiacin(s)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig06
Figure 6
Laspartomycin
10.1128/9781555815929/f1190-01_thmb.gif
10.1128/9781555815929/f1190-01.gif
Figure 6
Laspartomycin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig07
Figure 7
WAP-8294A complex
10.1128/9781555815929/f1190-02_thmb.gif
10.1128/9781555815929/f1190-02.gif
Figure 7
WAP-8294A complex
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig08
Figure 8
LY-301621
10.1128/9781555815929/f1191-01_thmb.gif
10.1128/9781555815929/f1191-01.gif
Figure 8
LY-301621
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig09
Figure 9
Diperamycin
10.1128/9781555815929/f1191-02_thmb.gif
10.1128/9781555815929/f1191-02.gif
Figure 9
Diperamycin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig10
Figure 10
TAN 1057 complex
10.1128/9781555815929/f1192-01_thmb.gif
10.1128/9781555815929/f1192-01.gif
Figure 10
TAN 1057 complex
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig11
Figure 11
GE 2270A
10.1128/9781555815929/f1193-01_thmb.gif
10.1128/9781555815929/f1193-01.gif
Figure 11
GE 2270A
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig12
Figure 12
M-1396
10.1128/9781555815929/f1194-01_thmb.gif
10.1128/9781555815929/f1194-01.gif
Figure 12
M-1396
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig13
Figure 13
Epicatechin gallate
10.1128/9781555815929/f1195-01_thmb.gif
10.1128/9781555815929/f1195-01.gif
Figure 13
Epicatechin gallate
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig14
Figure 14
MC-21 A
10.1128/9781555815929/f1195-02_thmb.gif
10.1128/9781555815929/f1195-02.gif
Figure 14
MC-21 A
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig15
Figure 15
Sesquiterpenoids (A. gilvescens)
10.1128/9781555815929/f1195-03_thmb.gif
10.1128/9781555815929/f1195-03.gif
Figure 15
Sesquiterpenoids (A. gilvescens)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig16
Figure 16
Xanthatin
10.1128/9781555815929/f1195-04_thmb.gif
10.1128/9781555815929/f1195-04.gif
Figure 16
Xanthatin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig17
Figure 17
Aaptamines
10.1128/9781555815929/f1195-05_thmb.gif
10.1128/9781555815929/f1195-05.gif
Figure 17
Aaptamines
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig18
Figure 18
ECO-0501
10.1128/9781555815929/f1196-01_thmb.gif
10.1128/9781555815929/f1196-01.gif
Figure 18
ECO-0501
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig19
Figure 19
Dichlorophenyl analogs
10.1128/9781555815929/f1196-02_thmb.gif
10.1128/9781555815929/f1196-02.gif
Figure 19
Dichlorophenyl analogs
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig20
Figure 20
Benzylidene rhodamine
10.1128/9781555815929/f1196-03_thmb.gif
10.1128/9781555815929/f1196-03.gif
Figure 20
Benzylidene rhodamine
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig21
Figure 21
Chorismate synthetase inhibitors
10.1128/9781555815929/f1197-01_thmb.gif
10.1128/9781555815929/f1197-01.gif
Figure 21
Chorismate synthetase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig22
Figure 22
A-358 (shikimate dehydroquinate synthase inhibitor)
10.1128/9781555815929/f1197-02_thmb.gif
10.1128/9781555815929/f1197-02.gif
Figure 22
A-358 (shikimate dehydroquinate synthase inhibitor)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig23
Figure 23
Methanofusidic acid
10.1128/9781555815929/f1197-03_thmb.gif
10.1128/9781555815929/f1197-03.gif
Figure 23
Methanofusidic acid
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig24
Figure 24
Pol IIIC inhibitor (HBEMAU)
10.1128/9781555815929/f1198-01_thmb.gif
10.1128/9781555815929/f1198-01.gif
Figure 24
Pol IIIC inhibitor (HBEMAU)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig25
Figure 25
Pol IIIC inhibitors
10.1128/9781555815929/f1198-02_thmb.gif
10.1128/9781555815929/f1198-02.gif
Figure 25
Pol IIIC inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig26
Figure 26
Lydicamycin complex
10.1128/9781555815929/f1199-01_thmb.gif
10.1128/9781555815929/f1199-01.gif
Figure 26
Lydicamycin complex
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig27
Figure 27
Tetrahydroquinoline derivatives
10.1128/9781555815929/f1199-02_thmb.gif
10.1128/9781555815929/f1199-02.gif
Figure 27
Tetrahydroquinoline derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig28
Figure 28
Phenylpiperidine derivatives
10.1128/9781555815929/f1200-01_thmb.gif
10.1128/9781555815929/f1200-01.gif
Figure 28
Phenylpiperidine derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig29
Figure 29
Biaryl acid derivative
10.1128/9781555815929/f1200-02_thmb.gif
10.1128/9781555815929/f1200-02.gif
Figure 29
Biaryl acid derivative
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig30
Figure 30
PDL 117230 and PDL 117229 (Biaryl derivatives)
10.1128/9781555815929/f1200-03_thmb.gif
10.1128/9781555815929/f1200-03.gif
Figure 30
PDL 117230 and PDL 117229 (Biaryl derivatives)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig31
Figure 31
PhenylalanyltRNA synthase inhibitors (spirocyclic furan and pyrrolidine derivatives)
10.1128/9781555815929/f1201-01_thmb.gif
10.1128/9781555815929/f1201-01.gif
Figure 31
PhenylalanyltRNA synthase inhibitors (spirocyclic furan and pyrrolidine derivatives)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig32
Figure 32
CB 102930 (phenylalanyl-tRNA synthase inhibitor)
10.1128/9781555815929/f1201-02_thmb.gif
10.1128/9781555815929/f1201-02.gif
Figure 32
CB 102930 (phenylalanyl-tRNA synthase inhibitor)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig33
Figure 33
Tyrosyl-tRNA synthetase inhibitor
10.1128/9781555815929/f1201-03_thmb.gif
10.1128/9781555815929/f1201-03.gif
Figure 33
Tyrosyl-tRNA synthetase inhibitor
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig34
Figure 34
Methionyl-tRNA synthase inhibitors
10.1128/9781555815929/f1202-01_thmb.gif
10.1128/9781555815929/f1202-01.gif
Figure 34
Methionyl-tRNA synthase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig35
Figure 35
Methionyl-tRNA synthase inhibitors
10.1128/9781555815929/f1202-02_thmb.gif
10.1128/9781555815929/f1202-02.gif
Figure 35
Methionyl-tRNA synthase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig36
Figure 36
REP 8839
10.1128/9781555815929/f1203-01_thmb.gif
10.1128/9781555815929/f1203-01.gif
Figure 36
REP 8839
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig37
Figure 37
SB 203207
10.1128/9781555815929/f1203-02_thmb.gif
10.1128/9781555815929/f1203-02.gif
Figure 37
SB 203207
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig38
Figure 38
Pantothenate kinase inhibitors
10.1128/9781555815929/f1203-03_thmb.gif
10.1128/9781555815929/f1203-03.gif
Figure 38
Pantothenate kinase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig39
Figure 39
Benzoimidazole derivatives
10.1128/9781555815929/f1203-04_thmb.gif
10.1128/9781555815929/f1203-04.gif
Figure 39
Benzoimidazole derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig40
Figure 40
Vancoresmycin
10.1128/9781555815929/f1204-01_thmb.gif
10.1128/9781555815929/f1204-01.gif
Figure 40
Vancoresmycin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig41
Figure 41
Flavonoid chalcone derivatives
10.1128/9781555815929/f1204-02_thmb.gif
10.1128/9781555815929/f1204-02.gif
Figure 41
Flavonoid chalcone derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig42
Figure 42
AR-100 (iclaprim)
10.1128/9781555815929/f1204-03_thmb.gif
10.1128/9781555815929/f1204-03.gif
Figure 42
AR-100 (iclaprim)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig43
Figure 43
XRP 2868
10.1128/9781555815929/f1205-01_thmb.gif
10.1128/9781555815929/f1205-01.gif
Figure 43
XRP 2868
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig44
Figure 44
Benzopyran stilbene
10.1128/9781555815929/f1206-01_thmb.gif
10.1128/9781555815929/f1206-01.gif
Figure 44
Benzopyran stilbene
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig45
Figure 45
AVE 6971
10.1128/9781555815929/f1206-02_thmb.gif
10.1128/9781555815929/f1206-02.gif
Figure 45
AVE 6971
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig46
Figure 46
FabI inhibitor: 1,4-benzodiazepine derivative
10.1128/9781555815929/f1207-01_thmb.gif
10.1128/9781555815929/f1207-01.gif
Figure 46
FabI inhibitor: 1,4-benzodiazepine derivative
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig47
Figure 47
2-Mercaptoquinoline
10.1128/9781555815929/f1207-02_thmb.gif
10.1128/9781555815929/f1207-02.gif
Figure 47
2-Mercaptoquinoline
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig48
Figure 48
Coumarin derivative
10.1128/9781555815929/f1207-03_thmb.gif
10.1128/9781555815929/f1207-03.gif
Figure 48
Coumarin derivative
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig49
Figure 49
RU-79115
10.1128/9781555815929/f1208-01_thmb.gif
10.1128/9781555815929/f1208-01.gif
Figure 49
RU-79115
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig50
Figure 50
DNA gyrase B inhibitor: pyrazolo derivatives
10.1128/9781555815929/f1208-02_thmb.gif
10.1128/9781555815929/f1208-02.gif
Figure 50
DNA gyrase B inhibitor: pyrazolo derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig51
Figure 51
Cyclothialidine
10.1128/9781555815929/f1208-03_thmb.gif
10.1128/9781555815929/f1208-03.gif
Figure 51
Cyclothialidine
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig52
Figure 52
Novobiocin derivatives
10.1128/9781555815929/f1209-01_thmb.gif
10.1128/9781555815929/f1209-01.gif
Figure 52
Novobiocin derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig53
Figure 53
Indazole derivatives (DNA gyrase B inhibitor)
10.1128/9781555815929/f1209-02_thmb.gif
10.1128/9781555815929/f1209-02.gif
Figure 53
Indazole derivatives (DNA gyrase B inhibitor)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig54
Figure 54
Mansonone F
10.1128/9781555815929/f1209-03_thmb.gif
10.1128/9781555815929/f1209-03.gif
Figure 54
Mansonone F
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig55
Figure 55
Indolquinoline
10.1128/9781555815929/f1210-01_thmb.gif
10.1128/9781555815929/f1210-01.gif
Figure 55
Indolquinoline
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig56
Figure 56
Isoquinoline
10.1128/9781555815929/f1210-02_thmb.gif
10.1128/9781555815929/f1210-02.gif
Figure 56
Isoquinoline
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig57
Figure 57
5S-penems: signal peptidase inhibitors
10.1128/9781555815929/f1210-03_thmb.gif
10.1128/9781555815929/f1210-03.gif
Figure 57
5S-penems: signal peptidase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig58
Figure 58
Isoxazolinones
10.1128/9781555815929/f1210-04_thmb.gif
10.1128/9781555815929/f1210-04.gif
Figure 58
Isoxazolinones
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig59
Figure 59
Pyrimido[4,5]pyrimidine derivatives
10.1128/9781555815929/f1211-01_thmb.gif
10.1128/9781555815929/f1211-01.gif
Figure 59
Pyrimido[4,5]pyrimidine derivatives
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig60
Figure 60
Netropsin and distamycin
10.1128/9781555815929/f1211-02_thmb.gif
10.1128/9781555815929/f1211-02.gif
Figure 60
Netropsin and distamycin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig61
Figure 61
HARP analogs
10.1128/9781555815929/f1211-03_thmb.gif
10.1128/9781555815929/f1211-03.gif
Figure 61
HARP analogs
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig62
Figure 62
Nematophin
10.1128/9781555815929/f1212-01_thmb.gif
10.1128/9781555815929/f1212-01.gif
Figure 62
Nematophin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig63
Figure 63
Pyrrolobenzodiazepines
10.1128/9781555815929/f1212-02_thmb.gif
10.1128/9781555815929/f1212-02.gif
Figure 63
Pyrrolobenzodiazepines
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig64
Figure 64
Cremimycin
10.1128/9781555815929/f1213-01_thmb.gif
10.1128/9781555815929/f1213-01.gif
Figure 64
Cremimycin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig65
Figure 65
Benzothiazolyl cephems
10.1128/9781555815929/f1213-02_thmb.gif
10.1128/9781555815929/f1213-02.gif
Figure 65
Benzothiazolyl cephems
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig66
Figure 66
Classification, cephem group VI
10.1128/9781555815929/f1214-01_thmb.gif
10.1128/9781555815929/f1214-01.gif
Figure 66
Classification, cephem group VI
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig67
Figure 67
T-91825
10.1128/9781555815929/f1214-02_thmb.gif
10.1128/9781555815929/f1214-02.gif
Figure 67
T-91825
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig68
Figure 68
TAK-599
10.1128/9781555815929/f1215-01_thmb.gif
10.1128/9781555815929/f1215-01.gif
Figure 68
TAK-599
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig69
Figure 69
S-3578
10.1128/9781555815929/f1215-02_thmb.gif
10.1128/9781555815929/f1215-02.gif
Figure 69
S-3578
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig70
Figure 70
BAL 9141
10.1128/9781555815929/f1215-03_thmb.gif
10.1128/9781555815929/f1215-03.gif
Figure 70
BAL 9141
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig71
Figure 71
BMS-247243
10.1128/9781555815929/f1216-01_thmb.gif
10.1128/9781555815929/f1216-01.gif
Figure 71
BMS-247243
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig72
Figure 72
RWJ-54428
10.1128/9781555815929/f1216-02_thmb.gif
10.1128/9781555815929/f1216-02.gif
Figure 72
RWJ-54428
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig73
Figure 73
RWJ-333441 prodrugs
10.1128/9781555815929/f1217-01_thmb.gif
10.1128/9781555815929/f1217-01.gif
Figure 73
RWJ-333441 prodrugs
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig74
Figure 74
Water solubility of anti-MRSA cephems
10.1128/9781555815929/f1217-02_thmb.gif
10.1128/9781555815929/f1217-02.gif
Figure 74
Water solubility of anti-MRSA cephems
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig75
Figure 75
RWJ-442831, prodrug of RWJ-54428
10.1128/9781555815929/f1218-01_thmb.gif
10.1128/9781555815929/f1218-01.gif
Figure 75
RWJ-442831, prodrug of RWJ-54428
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig76
Figure 76
ME-1209 (CP-6679)
10.1128/9781555815929/f1218-02_thmb.gif
10.1128/9781555815929/f1218-02.gif
Figure 76
ME-1209 (CP-6679)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig77
Figure 77
BC 1175
10.1128/9781555815929/f1218-03_thmb.gif
10.1128/9781555815929/f1218-03.gif
Figure 77
BC 1175
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig78
Figure 78
Imidazolopyridinium cephalosporin
10.1128/9781555815929/f1218-04_thmb.gif
10.1128/9781555815929/f1218-04.gif
Figure 78
Imidazolopyridinium cephalosporin
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig79
Figure 79
LB-11058
10.1128/9781555815929/f1219-01_thmb.gif
10.1128/9781555815929/f1219-01.gif
Figure 79
LB-11058
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig80
Figure 80
PGE-69337410 and PGE-69337410
10.1128/9781555815929/f1219-02_thmb.gif
10.1128/9781555815929/f1219-02.gif
Figure 80
PGE-69337410 and PGE-69337410
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig81
Figure 81
L-763863
10.1128/9781555815929/f1220-01_thmb.gif
10.1128/9781555815929/f1220-01.gif
Figure 81
L-763863
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig82
Figure 82
L-786392
10.1128/9781555815929/f1220-02_thmb.gif
10.1128/9781555815929/f1220-02.gif
Figure 82
L-786392
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig83
Figure 83
Cleavage of the carbapenem ring
10.1128/9781555815929/f1221-01_thmb.gif
10.1128/9781555815929/f1221-01.gif
Figure 83
Cleavage of the carbapenem ring
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig84
Figure 84
Dithiocarbamate (BO-3482)
10.1128/9781555815929/f1221-02_thmb.gif
10.1128/9781555815929/f1221-02.gif
Figure 84
Dithiocarbamate (BO-3482)
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig85
Figure 85
J-111,347 and analogs
10.1128/9781555815929/f1222-01_thmb.gif
10.1128/9781555815929/f1222-01.gif
Figure 85
J-111,347 and analogs
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig86
Figure 86
Pyrrolidinyl carbapenems
10.1128/9781555815929/f1223-01_thmb.gif
10.1128/9781555815929/f1223-01.gif
Figure 86
Pyrrolidinyl carbapenems
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig87
Figure 87
β-Methyl carbapenems with oxime and imino moieties
10.1128/9781555815929/f1223-02_thmb.gif
10.1128/9781555815929/f1223-02.gif
Figure 87
β-Methyl carbapenems with oxime and imino moieties
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig88
Figure 88
SM-216601
10.1128/9781555815929/f1224-01_thmb.gif
10.1128/9781555815929/f1224-01.gif
Figure 88
SM-216601
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig89
Figure 89
CS-834
10.1128/9781555815929/f1224-02_thmb.gif
10.1128/9781555815929/f1224-02.gif
Figure 89
CS-834
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig90
Figure 90
CP-5068
10.1128/9781555815929/f1224-03_thmb.gif
10.1128/9781555815929/f1224-03.gif
Figure 90
CP-5068
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig91
Figure 91
Benzonaphthyridones
10.1128/9781555815929/f1225-01_thmb.gif
10.1128/9781555815929/f1225-01.gif
Figure 91
Benzonaphthyridones
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig92
Figure 92
Saccharomicins
10.1128/9781555815929/f1226-01_thmb.gif
10.1128/9781555815929/f1226-01.gif
Figure 92
Saccharomicins
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig93
Figure 93
PTK 0796
10.1128/9781555815929/f1227-01_thmb.gif
10.1128/9781555815929/f1227-01.gif
Figure 93
PTK 0796
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig94
Figure 94
VIC-105555
10.1128/9781555815929/f1227-02_thmb.gif
10.1128/9781555815929/f1227-02.gif
Figure 94
VIC-105555
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig95
Figure 95
DK-507k
10.1128/9781555815929/f1228-01_thmb.gif
10.1128/9781555815929/f1228-01.gif
Figure 95
DK-507k
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig96
Figure 96
WCK 771
10.1128/9781555815929/f1228-02_thmb.gif
10.1128/9781555815929/f1228-02.gif
Figure 96
WCK 771
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig97
Figure 97
DQ-113
10.1128/9781555815929/f1229-01_thmb.gif
10.1128/9781555815929/f1229-01.gif
Figure 97
DQ-113
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig98
Figure 98
DX-619
10.1128/9781555815929/f1229-02_thmb.gif
10.1128/9781555815929/f1229-02.gif
Figure 98
DX-619
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig99
Figure 99
AZD 2563
10.1128/9781555815929/f1229-03_thmb.gif
10.1128/9781555815929/f1229-03.gif
Figure 99
AZD 2563
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig100
Figure 100
Oxazolidinones
10.1128/9781555815929/f1229-04_thmb.gif
10.1128/9781555815929/f1229-04.gif
Figure 100
Oxazolidinones
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig101
Figure 101
BB-83698
10.1128/9781555815929/f1230-01_thmb.gif
10.1128/9781555815929/f1230-01.gif
Figure 101
BB-83698
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
/content/10.1128/9781555815929.ch49.ch49fig102
Figure 102
Methionine aminopeptidase inhibitors
10.1128/9781555815929/f1230-02_thmb.gif
10.1128/9781555815929/f1230-02.gif
Figure 102
Methionine aminopeptidase inhibitors
Citation:
Bryskier A.
2005.
Agents against Methicillin-Resistant Staphylococcus aureus,
p 1183-1238.
In
Bryskier, M.D. A (ed),
Antimicrobial Agents.
ASM Press, Washington, DC.
doi: 10.1128/9781555815929.ch49
References
/content/book/10.1128/9781555815929.ch49
1.
Akona-Koffi C,, Guessennd N,, Gbonon U,, Faye-Ketté H,, Dosso M, 2004, Methicillin-resistance of S. aureus in Abidjan (1998-2001), a new hospital problem, Med Mal Infect, 34, 132– 136.
2.
Alcavaz LE,, Blanco SE,, Puig ON,, Thomas T,, Ferretti FN, 2000, Antibacterial activity of flavonoids against methicillin-resistant S. aureus strain, J Theor Biol, 205, 231– 240.
3.
Alexander J,, Binda DS,, Glan JD,, Holahan MA,, Reyner MC,, Rork GS,, Sitko GR,, Stanieri MT,, Stupienski RF,, Veerapanne H,, Cook JJ, 1996, Investigation of (oxodioxolenyl) methyl carbamates as non chiral bioreversible prodrug moieties for chiral amines, J Med Chem, 39, 480– 486.
4.
Ali A,, Aster SD,, Graham DW,, Patel GF,, Taylor GE,, Tolman RL,, Painter RE, et al, 2001, Design and synthesis of novel antibacterial agents with inhibitory activity against DNA polymerase III, Bioorg Med Chem Lett, 11, 2185– 2188.
5.
Alvarez-Bravo J,, Kurata S,, Natori S, 1994, Novel synthetic antimicrobial peptides effective against methicillin-resistant S. aureus, Biochem J, 302, 535– 538.
6.
Anderegg TR,, Biedenbach DJ,, Jones RN, 2002, In vitro evaluation of AZD 2563, a novel oxazolidinone against 603 recent staphylococcal isolates, Antimicrob Agents Chemother, 46, 2662– 2664.
7.
Angehrn P,, Buchmann S,, Funk C,, Goetschi E,, Gmuender H,, Hebeisen P,, et al, 2004, New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine, J Med Chem, 47, 1487– 1513.
8.
Arvidson S,, Tegmark K, 2001, Regulation of virulence determinants in S. aureus, Intern J Med Microb, 291, 159– 170.
9.
Ascher G,, Heilmayer N,, Hildebrandt J,, Wieser J, 2003, Synthesis and SAR of novel cephalosporin-azomethines, broad spectrum antibacterial with anti-MRSA activity, 43rd Intersci Conf Antimicrob Agents Chemother, abstract F-543.
10.
Bacqué C,, Barrière JC,, Berthaud N,, Desmezeau F,, Dutka-Mallens S,, Dutuc-Rosset G,, Ronan B, 2001, Design, synthesis, and in vitro evaluation of XRP 2868, a new oral streptogramin, 41st Intersci Conf Antimicrob Agents Chemother.
11.
Banwell MG,, Crasto CF,, Easton CJ,, Forrest AK,, Karoli T,, March DR,, Mensah L, et al, 2000, Analogues of SB-203207 as inhibitors of tRNA synthetase, Bioorg Med Chem Lett, 10, 2263– 2266.
12.
Bardouniotis E,, Thalakada R,, Walsh N,, Dorsey M,, Schmid MB,, Kaplan N, 2004, In vitro activities of novel bacterial enoyl-ACP reductase inhibitors, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-316.
13.
Barry AL, 1988, In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents, Antimicrob Agents Chemother, 32, 150– 152.
14.
Bartel S,, Endermann R,, Guarnieri W,, Häbich D,, Härber M,, Kroll HP,, Raddatz S,, Rield B,, Rosentreter U,, Ruppel M,, Stolle A,, Wild H, 1998, Synthesis and antibacterial activity of novel hetero aryl oxazilidinones. I. Benzoxazone and benzothiazole oxazolidinones, 38th Intersci Conf Antimicrob Agents Chemother, abstract F-131.
15.
Bemer P,, Juvin ME,, Bryskier A,, Drugeon H, 2003, In vivo activities of a new lipopeptide HMR1043 against susceptible and resistant gram-positive isolates, Antimicrob Agents Chemother, 47, 3025– 3029.
16.
Berry V,, Satterfield J,, Singley C,, Hunt E,, Woodnutt G, 1999, In vivo efficacy of the novel topical pleuromutilins, SB-247386 and SB-268091, 39th Intersci Conf Antimicrob Agents Chemother, abstract 1804, p 337.
17.
Blizzard TA,, Kim RM,, Morgan JD,, Chang J,, Kohler J,, Kilburn R,, Chapman K,, Hammond ML, 2002, Antibacterial activity of G-6 quaternary ammonium derivatives of a lipophilic vancomycin analogue, Bioorg Med Chem Lett, 12, 849– 852.
18.
Border DB,, Lease RA,, Jarolmen H,, Francis ND,, Fantini AA,, Falla T,, Aumelas A, 2001, Laspartamycin—lipopeptide antibiotic with a unique peptide core, 41st Intersci Conf Antimicrob Agents Chemother, abstract F-1154.
19.
Bozdogan B,, Appelbaum PC, 2004, Activity of DX 619, a new quinolone against vancomycin non-susceptible staphylococci, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-1940.
20.
Bozdogan B,, Esel D,, Whitener C,, Browne FA,, Appelbaum PC, 2003, Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center, J Antimicrob Chemother, 52, 864– 868.
21.
Braun DK,, Chien Y,, Farlow DS,, Phillips DS,, Nasilewska MM,, Zeckel M, 2001, Oritavancin (LY 333328), a dose escalating on safety and pharmacokinetic studies in patients, Eur Cong Chemother Microbiol Infect Dis Istambul, P 434.
22.
Bremner JB,, Coates JA,, Coghlan DR,, David DM,, Keller PA,, Pyne SG, 2002, The synthesis of a novel binaphthyl-based cyclicpeptoid with antibacterial activity, New J Chem, 26, 1549– 1551.
23.
Bryskier A,, Aszodi J,, Chantot J-F, 1994, Parenteral cephalosporin classification, Expert Opin Invest Drugs, 3, 145– 171.
24.
Bugg TD,, Wright GD,, Dutka-Mahlens S,, Arthur M,, Courvalin P,, Walsh CT, 1991, Molecular basis for vancomycin resistance in Enterococcus faecium BM 4147, biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance protein Van H and Van A, Biochemistry, 30, 10408– 10415.
25.
Bürli R,, Ge Y,, White S, et al, 2002, DNA binding ligands with excellent antibiotic potency against drug-resistant gram-positive bacteria, Bioorg Med Chem Lett, 12, 2591– 2594.
26.
Bush K,, Abbanat D,, Davies T,, Dudley M,, Blais J,, Hilliard J,, Wira E,, Queenan A,, Foleno B, 2003, In vitro and in vivo antibacterial activity of RWJ 442831, a prodrug of the anti-MRSA cephalosporin RWJ 4428, 43rd Intersci Conf Antimicrob Agents Chemother, abstract F-548.
27.
Calcul L,, Longeon A,, Al Mourabit A,, Guyot M,, Bourguet-Koudracki M-L, 2003, Novel alkaloids of the aaptamine class from an Indonesian marine sponge of the genus Xestospongia, Tetrahedron, 59, 6539– 6544.
28.
Chana S,, Chapman S,, Charles I,, Cockerill S,, Dolman M,, Goulding E,, Hawkins A, et al, 2001, Synthesis and SAR of novel inhibitors of the shikimate pathway enzyme dehydroquinate synthase, 41st Intersci Conf Antimicrob Agents Chemother, abstract F-1793.
29.
Chen Z,, White RE,, Laughlin KJ, et al, 2000, Discovery of 3-dithiocarbamoylcephalosporins highly active in vitro against resistant gram-positive bacteria, 40th Intersci Conf Antimicrob Agents Chemother, abstract F-1068.
30.
Cho A,, Glinka TW,, Ludnikow M,, Fan AT,, Wang M,, Hecker SJ, 2001a, New anti-MRSA cephalosporins with a basic aminopyridine at the C-7 position, Bioorg Med Chem Lett, 11, 137– 140.
31.
Cho YR,, Kim MJ,, Joo HR,, Kim HS,, Youn H, 2001b, The in vitro activity of LB 11058, a new parenteral cephalosporin with activity against multi-resistant gram-positive bacteria, 41st Intersci Conf Antimicrob Agents Chemother, abstract F-330.
32.
Choi KH,, Hong JS,, Kim SK,, Lee DK,, Yoon SJ,, Choi EC, 1997, In vitro and in vivo activities of DW-116, a new fluoroquinolone, J Antimicrob Chemother, 39, 509– 514.
33.
Choudhry AE,, Mandichak TL,, Brosey JP,, Egolf RW,, Kingland C,, Begley TP,, Seefeld MA,, Ku TW,, Brown JR,, Zulacain M,, Rathman K, 2003, Inhibitors of pantothenate kinase, novel antibiotics for staphylococcal infections, Antimicrob Agents Chemother, 47, 2051– 2055.
34.
Clarke TE,, Buzadzija K,, Dorsey M, 2004, High resolution 3-dimension structural characterization of Staphylococcus enoyl-ACP-reductase ternary complex, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-1527.
35.
Clough J,, Chen S,, Gordon EM,, Hackbarth C,, Lam S,, Trias J,, White RJ,, Candiani G,, Donadio S,, Romano G,, Ciabatti R,, Jacobs JW, 2003, Combinatiorial modification of natural products, synthesis and in vitro analysis of derivatives of triazolyl peptide antibiotic GE 2270 A, A-ring modifications, Bioorg Med Chem Lett, 13, 3409– 3414.
36.
Cordova SP,, Heath CH,, McGechie DB,, Keil AD,, Beers HY,, Riley TV, 2004, Methicillin-resistant S. aureus bacteremia in Western Australia teaching hospital, 1997-1999: risk factors, outcomes and implications for management, J Hosp Infect, 56, 22– 28.
37.
Cosgrove SE,, Sakoulas G,, Perencevich EN,, Schwaber MJ,, Karchmer AW,, Carmeli Y, 2003, Comparison of mortality associated with methicillin-resistant and methicillin-susceptible S. aureus bacteremia, a meta-analysis, Clin Infect Dis, 36, 53– 59.
38.
Cozzarelli NR, 1977, The mechanism of action of inhibitors of DNA synthesis, Annu Rev Biochem, 46, 641– 668.
39.
Critchley IA,, Blosser-Middleton RS,, Porter SP,, Loutit JS,, Jones ME,, Thornsberry C,, Karlowsky JA,, Sahm DF, 2002, Activity of oritavancin against clinical isolates of S. aureus collected from blood specimen in the United States, 42nd Intersci Conf Antimicrob Agents Chemother, abstract E-1452.
40.
Critchley IA,, Stone K,, Young C,, Ochsner U,, Guiles J,, Tarasow T,, Janjic N, 2004a, REP 8839, a novel methionyl tRNA synthetase inhibitor with potent activity against Staphylococcus aureus and Streptococcus pyogenes, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-728.
41.
Critchley IA,, Young C,, Stone K,, Ochsner U,, Dang C,, Janjic N, 2004b, Spectrum of activity of REP 8839, a new antibiotic for topical use, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-729.
42.
Cutler BR,, Cutler SJ,, Josling PD,, Wilson P, 2001, Activity of a novel, stable, allicin extract in liquid and cream formulations, against methicillin-resistant S. aureus including mupirocin-resistant MRSA, 41st Intersci Conf Antimicrob Agents Chemother, abstract 2279.
43.
Davis MW,, Buechter DD,, Schimmel P, 1994, Functional dissection of a predicted class-defining motif in a class II tRNA synthetase of unknown structure, Biochemistry, 33, 9904– 9911.
44.
Deresinski S, 2005, Methicillin-resistant Staphylococcus aureus, an evolutionary, epidemiologic, and therapeutic odyssey, Clin Infect Dis, 40, 562– 573.
45.
Diekema MJ,, Jones RN, 2001, Oxazolidinone antibiotics, Lancet, 358, 1975– 1982.
46.
Draghi DC,, Thornsberry C,, Jones ME,, Flamm RK,, Sahm DF,, Karlowsky JA, 2003, In vitro activity of CB 181963 against 1064 gram-positive and gram-negative pathogens, 43rd Intersci Conf Antimicrob Agents Chemother, abstract F-544.
47.
Dreier J,, Ofner C,, Stueber D,, Danel F,, Page MGP, 2001, Identifying new inhibitors of dihydropteroate synthase from S. aureus, 41th Intersci Conf Antimicrob Agents Chemother, abstract 1702.
48.
Drugeon HB,, Juvin ME,, Couturier C,, Bryskier A, 2002, Role of each component (RPR 202868 –PI) and RPR 132552 – PII in bactericidal synergism of XRP 2868 (a new oral semi synthetic streptogramin) against Streptococcus pneumoniae, H. influenzae and S. aureus, 42nd Intersci Conf Antimicrob Agents Chemother, abstract F-2116.
49.
Dugourd D,, Rubinchik E,, Erfle DJ,, Siu R,, Fenn J,, Patsetka C,, Clement JJ, 2004, M-1396, a novel lipopeptide antimicrobial active against antibiotic resistant and sensitive gram-positive bacteria, 44th Intersci Conf Antimicrob Agents Chemother.
50.
Dushin RG,, Wang TZ,, Fortier G,, Tera S,, Papamichelakir H,, Richard L,, Sellstedt J,, Stahl S, 2002, Synthesis of A-98-6446, a semi-synthetic mannopeptimycin derivative, 42nd Intersci Conf Antimicrob Agents Chemother, abstract F-352.
51.
Duvold T,, Jorgensen A,, Andersen NR,, Henriksen AS,, Sorensen MD,, Björkling F, 2002, 17 S,20 S-Methanofusidic acid, a new potent fusidane antibiotic, Bioorg Med Chem Lett, 12, 3569– 3572.
52.
Eid CN,, Nicas T,, Mullen DL,, Loncharich RJ,, Paschal JW, 1997, Design, synthesis and potentiating activities against methicillin-resistant S. aureus of cyclic analogs of LY 301621, Bioorg Med Chem Lett, 7, 2087– 2092.
53.
Endersmann R,, Bartel S,, Guarnieri W,, Häbich D,, Härter M,, Kroll HP,, Raddatz S,, Rield B,, Rosentreter U,, Ruppelt M,, Stolle A,, Wild H, 1998, Synthesis and antibacterial activity of novel hetero aryl oxazolidinones. III. Activities against clinically important gram-positive pathogens, 38th Intersci Conf Antimicrob Agents Chemother, abstract F-129.
54.
Entenza JM,, Hohl P,, Heinze-Krauss I,, Glauser MP,, Moreillon P, 2002, BAL 9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis, Antimicrob Agents Chemother, 46, 171– 177.
55.
Felmingham D,, Robbin MJ,, Schackcloth J,, Denar C,, Williams J,, Bryskier A, 2004, Activity of XRP 2868 against S. pneumoniae, S. aureus, H. influenzae and ‘atypical’ respiratory tract pathogens, 44th Intersci Conf Antimicrob Agents Chemother.
56.
Finn J,, Hill J,, Ram S,, Morytko M,, Yu X,, Gimi R,, Silverman J,, Stem R,, et al, 2001, Novel antibacterial agents targeting methionyl-tRNA synthetase, a cheminformatic approach to convert HTS data into quality medicinal chemistry load, 41st Intersci Conf Antimicrob Agents Chemother, abstract 2140.
57.
Fritsche TR,, Kirby J,, Jones RN, 2004, Activity of tigecycline tested against 3498 Staphylococcus aureus: an assessment versus community-acquired ORSA, 44th Intersci Conf Antimicrob Agents Chemother, abstract C2-2000.
58.
Fujimura T,, Yamano Y,, Yoshida I,, Shimada J,, Kuwahara S, 2003, In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci, Antimicrob Agents Chemother, 47, 923– 931.
59.
Fukuoka T,, Ohya S,, Utsui Y,, Domon H,, Takenouchi T,, Koga T,, Masuda N, et al, 1997, In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem, Antimicrob Agents Chemother, 41, 2652– 2663.
60.
Funabashi Y,, Tsubotoni S,, Koyama K,, Katayama N,, Harada S, 1993, A new anti-MRSA dipeptide TAN-1057 A, Tetrahedron, 49, 13– 28.
61.
Fung-Tomc JC,, Clark J,, Minassian B,, Pucci M,, Tsai YH,, Gradelski E,, Lamb L,, Medina I,, et al, 2002, In vitro and in vivo activities of a novel cephalosporin, BMS 247243, against methicillin-resistant and -susceptible staphylococci, Antimicrob Agents Chemother, 46, 971– 976.
62.
Furumai T,, Eto K,, Sasaki T,, Higushi H,, Onaka H,, Saito N,, Fujita T,, Naoki N,, Igarashi Y, 2002, TPU-0037 A, B, C and D, novel lydicamycin congeners with anti-MRSA activity from Streptomyces platensis TP A0598, J Antibiot, 55, 873– 880.
63.
Gales AC,, Andrade SS,, Sader HS,, Jones RN, 2004, Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program, J Chemother, 16, 323– 328.
64.
Ge Y,, Touami S,, Critchley I,, Taylor M,, Baird E,, Bürli R,, Pennell A,, Moser H, 2001, Evaluating in vitro potency of GSQ 1530 a new class of antibiotic HARP, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1687.
65.
Ge Y,, Wu J,, Parekh B,, White S, 2001, Mechanistic study of a novel class of antibiotic HARP, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1686.
66.
Glinka T,, Huie K,, Cho A,, Ludwikow M,, Blais J,, Griffith D,, Hoecker S,, Dudley M, 2003, Relationships between structures, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroaryl thio) cephem: discovery of RWJ 333441 (MC 04546), Bioorg Med Chem, 11, 591– 600.
67.
Gravestock MB,, Acton DG,, Betts MJ,, Dennis M,, Hatter G,, McGregor A,, Swain ML,, Wilson RG,, Woods L,, Wookey A, 2003, New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains, Bioorg Med Chem Lett, 13, 4179– 4186.
68.
Griffith DC,, Hardford L,, Williams R,, Lee JL,, Dudley MN, 2003, In vivo antibacterial activity of RWJ 54428, a new cephalosporin with activity against gram-positive bacteria, Antimicrob Agents Chemother, 47, 43– 47.
69.
Grinius L,, Morris CM,, Curnow AW,, Hu EX,, Canty JF,, Mieling GE,, Wallace CD,, Zoutendam PH,, Demuth TPJ, 2001, Identification and characterization of new signal peptidase inhibitors among 5S-penem, 41st Intersci Conf Antimicrob Agents Chemother, abstract 388.
70.
Hackbarth CJ,, Chen DZ,, Lewis JG,, Clark K,, Mangold JB, et al, 2002, N-alkyl urea hydroxamic acid as a new class of peptide deformylase inhibitors with antibacterial activity, Antimicrob Agents Chemother, 46, 2752– 2764.
71.
Hadjivassileva T,, Thurston DE,, Taylor PW, 2004, Antibacterial activity of pyrrolobenzodiazepine dimers, a novel group of DNA-binding compounds, 44th Intersci Conf Antimicrob Agents Chemother, abstract 717.
72.
Hanaki H,, Akagi H,, Masara Y,, Otani T,, Hyodo A,, Hiramatsu K, 1995, TOC-39, a novel parenteral broad spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 39, 1120– 1126.
73.
Hanaki H,, Nomura S,, Akagi A,, Hiramatsu K, 2001, Improvement of water-soluble cephalosporin derivatives having antibacterial activity against methicillin-resistant Staphylococcus aureus, Chemotherapy, 47, 170– 176.
74.
Hashizume H,, Igarashi M,, Hattori S,, Hamada M,, Takeuchi T, 2001, Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities, J Antibiot, 54, 1054– 1059.
75.
Hattori K,, Yamada A,, Kuroda S,, Chiba T,, Murata M,, Sakane K, 2002, Synthesis and antibacterial evaluation of novel 2-[N-imidoyl pyrrolidinyl] carbapenem, Bioorg Med Chem Lett, 12, 383– 386.
76.
He X,, McEtwee-Reeve A,, Desai UR,, Kellog GE,, Reynolds KA, 2004a, 1,2-Dithiole-3-ones as potent inhibitor of the bacterial 3-ketoacyl carrier protein synthase II (FabH), Antimicrob Agents Chemother, 48, 3092– 3102.
77.
He Y,, Yang J,, Wu B,, Risen L,, Swayze EE, 2004b, Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents, Bioorg Med Chem, 14, 1217– 1220.
78.
Hebeisen P,, Heinz-Krauss I,, Anghern P,, Hilh P,, Page MGP,, Then RL, 2001, In vitro and in vivo properties of Ro 63-9141, a novel broad spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 45, 825– 836.
79.
Hecker SJ,, Calkins T,, Price ME,, Huie K,, Chen S,, Glinka TW,, Dudley MN, 2003, Prodrugs of cephalosporin RWJ 333341 (MC 04546) with improved aqueous solubility, Antimicrob Agents Chemother, 47, 2043– 2046.
80.
Heffron S,, Jurnak F, 2000, Structure of EFTu complex with triazolyl peptide antibiotic determined at 2.35Å resolution: atomic basis for GE 2270 A inhibition of EFtu, Biochemistry, 39, 37– 45.
81.
Hibasami H,, Midorikawa Y,, Gasaluck P,, Yoshimara H,, Masuji A,, Takaji S,, Nakashima K,, Imai M, 1991, Bactericidal effect of 15-deoxyspergualin on Staphylococcus aureus, Chemotherapy (Basel), 37, 202– 205.
82.
Hill J,, Finn J,, Lazarova T,, Morytko M,, Silverman J,, Oliver N,, Laganas V,, Li TC,, Keith D, 2001a, Novel lipopeptide. 3. Synthesis and biological activity of kynurenine modified analogs of daptomycin, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1152.
83.
Hill J,, Finn J,, Parr I,, Silverman J,, Oliver N,, Laganas V,, Li TC,, Keith D, 2001b, Novel lipopeptide. 2. Synthesis and biological activity of aromatic amide analogs of daptomycin, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1151.
84.
Hill J,, Finn J,, Parr I,, Yu X,, Morytko M,, Silverman J,, Oliver N,, Laganas V,, Li TC,, Keith D, 2001c, Novel lipopeptide. 1. Synthesis and biological activity of ornithine amino amide analogues of daptomycin, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1150.
85.
Hill J,, Finn J,, Yu X,, Wang Z,, Silverman J,, Oliver N,, Gallant P,, Wendler P,, Keith D, 2001d, Synthesis and activity of spirocyclic tetrahydrofurans as inhibitors of phenylalanine-tRNA synthase, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1707.
86.
Hill J,, Siedlecki J,, Parr I,, Morytko M,, Yu X,, Zhang Y,, Silverman J, et al, 2003, Synthesis and biological activity of N-acylated ornithine analogs of daptomycin, Bioorg Med Chem Lett, 13, 4187– 4191.
87.
Himmler T,, Pirro F,, Schmer N, 1998, Synthesis and antibacterial in vitro activity of novel analogues of nematophin, Bioorg Med Chem Lett, 8, 2045– 2050.
88.
Hiramatsu K,, Hanaki H,, Ito J,, Yabata K,, Oguri T,, Tenover FC, 1997, Methicillin-resistant S. aureus clinical strain with reduced vancomycin susceptibility, J Antimicrob Chemother, 40, 135– 136.
89.
Hoemann MZ,, Kumaravel G,, Xie RL,, Rossi RF,, Meyer S,, Sidhu A,, Cuny GD,, Hauske JR, 2000, Potent in vitro methicillin-resistant Staphylococcus aureus activity of 2-(1-H-indol-3-yl) quinoline derivative, Bioorg Med Chem Lett, 10, 2675– 2678.
90.
Hoemann MZ,, Xie RL,, Rossi RF,, Meyer S,, Sidhu A,, Cuny GD,, Hauske JR, 2002, Potent in vitro methicillin-resistant S. aureus activity of 2-(1-H-indol-3-yl) tetrahydroquinoline derivatives, Bioorg Med Chem Lett, 12, 129– 132.
91.
Hopmann C,, Kurz M,, Brönstrup M,, Wink J,, Le Beller D, 2002, Isolation and structure elucidation of vancoresmycin, a new antibiotic from Amycolatopsis ST 101170, Tetrahedron, 43, 435– 438.
92.
Howard JM,, Moris CM,, Grinius L,, Renick PJ,, Morris TW,, Wallace CD,, Koenigs PM,, Li M,, Neuman JF, 2001, Using membrane activity to determine the fate of signal peptidase inhibitors with antibacterial properties, 41st Intersci Conf Antimicrob Agents Chemother, abstract 1710.
93.
Howe RA,, Wootton M,, Noel AR,, Bowker KE,, Walsh TR,, MacGowan AP, 2003, Activity of AZD 2563, a novel oxazolidi-none, against Staphylococcus aureus strains with reduced susceptibility to vancomycin and linezolid, Antimicrob Agents Chemother, 47, 3651– 3652.
94.
Hu W,, Bürli RW,, Kaizerman JA,, Johnson KW,, Gross MI,, Iwamoto M,, Jones P,, Lofland D,, Difuntorum S,, Chen H,, Bozdogan B,, Appelbaum PC,, Moser HE, 2004, DNA binding ligands with improved in vitro and in vivo potency against drug resistant Staphylococcus aureus, J Med Chem, 47, 4352– 4355.
95.
Hu Y,, Helm JS,, Chen L,, Ye XY,, Walker S, 2003, Ramoplanin inhibits bacterial transglycosylase by binding as a dimer to lipid II, J Am Chem Soc, 125, 8736– 8737.
96.
Ida T,, Kurazono J,, Nagura J,, Sugano T,, Takayama Y,, Yoshida T,, Takase Y,, Takata H,, Sasaki T,, Komiya I, 2000, CP 5068, a new carbapenem, in vitro and in vivo activities against MRSA, 40th Intersci Conf Antimicrob Agents Chemother, abstract 1237.
97.
Igarashi M,, Tsuchida T,, Kinoshita N,, Kamijima M,, Sawa R,, Naganawa H,, Hamada M,, Takeuchi T,, Yamaziki K,, Ishizaka M, 1998, Cremimycin, a novel 19-membered lactam antibiotic from Streptomyces sp, J Antibiot, 51, 123– 129.
98.
Iinuma M,, Tosa H,, Tanaka T,, Asai F,, Kobayashi Y,, Shimano R,, Miyauchi K, 1996, Antibacterial activity of xanthones from guttiferaeous plants against methicillin-resistant S. aureus, J Pharm Pharmacol, 48, 861– 865.
99.
Inamura H,, Ohtake N,, Jona H,, Shimizu Amoriya M,, Sato H,, Sugimoto Y, et al, 2001, Dicationic dithio carbamate carbapenems with anti-MRSA, Bioorg Med Chem Lett, 9, 1571– 1578.
100.
Ishida H,, Fujikawa K,, Chiba M,, Tanaka M,, Otani T,, Sato K, 2004, DX 619, a novel des-F(6)-quinolone, mode of action against quinolone resistant MRSA, 44th Intersci Conf Antimicrob Agents Chemother, abstract F–1935.
101.
Ishikawa T,, Kamiyama K,, Nakayama Y,, Iizawa Y,, Okonogi K,, Miyake A, 2001a, Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-[(E)-2(1-alkyl imidazo[1, 2,b](pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and related compounds, J Antibiot, 54, 257– 277.
102.
Ishikawa T,, Matsunaga N,, Tawada H,, Kuroda N,, Nakayama Y,, Ishibashi Y,, Tomimoto M,, Ikeda Y,, Tagawa Y,, Iizawa Y,, Okonogi K,, Hashiguchi S,, Miyake A, 2003, TAK-599, a novel phosphono type prodrug of anti-MRSA cephalosporin T-91825, synthesis, physico-chemical and pharmacokinetic properties, Bioorg Med Chem Lett, 11, 2427– 2437.
103.
Ishikawa T,, Nakayama Y,, Tomimoto M,, Niwa S,, Kamiyama K,, Hashiguchi S,, Iizawa Y,, Okonogi K,, Miyake A, 2001b, Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parenteral administration, J Antibiot, 54, 364– 374.
104.
Isnansetyo A,, Kamei Y, 2003, MC21 A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp nov OBC 30 against methicillin-resistant S. aureus, Antimicrob Agents Chemother, 47, 480– 488.
105.
Jabes D,, Candiani G,, Romano G,, Rivas S,, Mafioli S,, Cibiatti R, 2003a, Efficacy of VIC-603, a new anti-gram-positive antibiotic in experimental infection, 43rd Intersci Conf Antimicrob Agents Chemother, abstract 2113.
106.
Jabes D,, Romano G,, Brunati C,, Rossi R,, Maffioli S,, Ciabatti R, 2003b, In vitro characteristics of VIC-603, a new anti-gram-positive antibiotic, 43rd Intersci Conf Antimicrob Agents Chemother, abstract 2112.
107.
Jacobs MR,, Bajaksouzian S,, Windau A,, Appelbaum PC,, Patel MV,, Gupte SV,, Bhagwat SS,, De Souza Nj,, Khorakiwala HF, 2004, In vitro activity of the new quinolone WCK 771 against staphylococci, Antimicrob Agents Chemother, 48, 3338– 3342.
108.
Jarraud S,, Mougel C,, Thioulouse J, et al, 2002, Relationships between S. aureus genetic background, virulence factors, agr groups (alleles), and human disease, Infect Immun, 70, 631– 641.
109.
Jarvest RL,, Armstrong SA,, Berge JM,, Brown P,, Elder JS,, Brown MJ,, et al, 2004, Definition of the heterocyclic pharmacophore of bacterial methionyl-tRNA synthase inhibitor, potent antibacterially active non-quinolone analogues, Bioorg Med Chem Lett, 14, 3937– 3941.
110.
Jarvest RL,, Berge JM,, Brown MJ,, Brown P,, Elder JS,, Forrest AK,, Houge-Frydrych CSV,, O’Hanlon PJ,, McNair DJ,, Rittenhouse S,, Sheppard RJ, 2003a, Optimisation of aryl substitution leading to potent methionyl-tRNA synthetase inhibitors with excellent gram-positive antibacterial activity, Bioorg Med Chem Lett, 13, 665– 668.
111.
Jarvest RL,, Berge JM,, Brown P,, Houge-Frydrych CSV,, O’Hanlon PJ,, McNair DJ,, Pope AJ,, Rittenhouse S, 2003b, Conformational restriction of methionyl-tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity, Bioorg Med Chem Lett, 13, 1265– 1268.
112.
Jarvest RL,, Berge JM,, Houge-Frydrych CSV,, Jason C,, Mensah LM,, O’Hanlon PJ,, Pope A,, Saldanha A,, Qiu X, 1999, Interaction of tyrosyl aryl dipeptide with S. aureus tyrosyl-tRNA synthetase, inhibition and crystal structure of a complex, Bioorg Med Chem Lett, 9, 2859– 2862.
113.
Jevitt LA,, Smith AJ,, Williams PP,, Raney PM,, McGowan JE Jr,, Tenover F, 2003, In vitro activities of daptomycin, linezolid, and dalfopristin-quinupristin against a challenge panel of staphylococci and enterococci including vancomycin-intermediate S. aureus and vancomycin-resistant E. faecium, Microb Drug Res, 9, 389– 393.
114.
Jevons M, 1961, Celbenin resistant staphylococci, Br Med J, 1, 124– 126.
115.
Johnson AP,, Warner M,, Carter M,, Livermoore DM, 2002, In vitro activity of a cephalosporin RWJ 54428 (MC 02479) against multidrug-resistant gram-positive cocci, Antimicrob Agents Chemother, 46, 321– 326.
116.
Johnson PD,, Aristoff PA,, Zurenko GE,, Schaadt RD,, Yagi BH,, Ford CW,, Hamel JC,, Stapert D,, Moerman JK, 2003, Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials, Bioorg Med Chem Lett, 13, 4197– 4200.
117.
Jones ME,, Klootwijk M,, Schmitz FJ,, Verhoef J, 2002a, Comparative activity of quinolone compounds moxifloxacin, grepafloxacin, trovafloxacin, levofloxacin, sparfloxacin, ofloxacin and oxazolidinone, linezolid against unrelated clinical isolates of ciprofloxacin-resistant and sensitive S. aureus, 42rd Intersci Conf Antimicrob Agents Chemother, abstract E-212.
118.
Jones RD,, Low DE,, Pfaller MA, 1999, Epidemiological trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other new compounds, Diagn Microbiol Infect Dis, 33, 101– 112.
119.
Jones RN,, Biedenbach DJ,, Johnsen DM,, Pfaller MA, 2001a, In vitro evaluation of BI 397, a novel glycopeptide antimibcrobial agent, J Chemother, 13, 244– 254.
120.
Jones RN,, Despande LM,, Mutnick AH,, Biedenback DJ, 2002b, In vitro evaluation of BAL 9141, a novel parenteral cephalosporin against oxacillin-resistant staphylococci, J Antimicrob Chemother, 50, 915– 922.
121.
Jones RN,, Fritsche TR,, Sader HS, 2004, Antimicrobial spectrum and activity of NVP PDF 713, a novel peptide deformylase inhibitor, tested against 1837 recent gram-positive clinical isolates, Diagn Microbiol Infect Dis, 49, 63– 65.
122.
Jones RN,, Hare RS,, Sabatelli FJ, and the Ziracin Susceptibility Testing Group, 2001b, In vitro gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials, a multicenter international trial, J Antimicrob Chemother, 47, 15– 25.
123.
Joo HY,, Bu SC,, Shin JE,, Cho YR,, Park D,, Kim SH,, Lee SH,, Youn H, 2001, The in vivo efficacy and pharmacokinetics of LB 11058, a new parenteral cephalosporin in experimental animals, 41st Intersci Conf Antimicrob Agents Chemother, abstract F-331.
124.
Judice JK,, Pace JL, 2003, Semi synthetic glycopeptide antibacterials, Bioorg Med Chem Lett, 13, 4165– 4168.
125.
Kaatz GW,, Moudgal VV,, Seo SM,, Hansen JB,, Kristiansen JE, 2003, Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus, Intern J Antimicrob Agents, 22, 254– 261.
126.
Kasai M,, Hatano S,, Kitagawa M,, Yoshimi A,, Nishimura K,, Mori N,, Sakai A,, Sugihara T, 1999, AS-924, a novel orally active bifunctional prodrug of ceftizoxime, synthesis and relationship between physico-chemical properties and oral absorption, Chem Pharm Bull, 47, 1081– 1088.
127.
Katayama N,, Fukusumi I,, Funabashi Y,, Iwahi T,, Ono H, 1993, TAN 1057 A-D, new antibiotics with potent antibacterial activity against methicillin-resistant S. aureus: taxonomy, fermentation and biological activity, J Antibiot, 46, 606– 613.
128.
Kato A,, Nakaya S,, Kakubo N,, Aiba Y,, Ohashi Y,, Hirata H, 1998, A new anti-MRSA antibiotic complex WAP-8294 A. I. Taxonomy, isolation and and biological activities, J Antibiot, 51, 929– 935.
129.
Kato A,, Nakaya S,, Suzuki N,, Ohashi Y,, Hirata H,, Fujii K,, Harada KI, 1997, WAP-8294 A, a novel anti-MRSA antibiotic produced by Lysobacter sp, J Am Chem Soc, 119, 6680– 6681.
130.
Kato N,, Yoshida T,, Nishino H,, Yoshikawa Y, 2000, 2-Mercaptoquinoline derivative, Horikoriku Seyaky Patent JP 12302760.
131.
Katz GW,, Mougdal VV,, Seo SM, 2002, Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus, J Antimicrob Chemother, 50, 833– 838.
132.
Kavanagh F,, Hervey A,, Robbins WJ, 1951, Antibiotic substances from basidiomycetes. VIII. Pleurotus mutilus and Pleurotus passeckerianus Pilat, PNAS, 37, 570– 574.
133.
Kawazoe K,, Tsubouchi Y,, Abdullah N,, Takaishi Y,, Shibata H,, Higati T,, Hori H,, Ogawa M, 2003, Sesquiterpenoids from Artemisia gilvescens, an anti-MRSA compound, J Nat Prod, 66, 538– 539.
134.
Kennedy G,, Viziano M,, Winders JA,, Cavallini P,, Gevi M,, Micheli F,, Rodegher P,, Seneci P,, Zumerle A, 2000, Studies on the novel anti-staphylococcal compound nematophin, Bioorg Med Chem Lett, 10, 1751– 1754.
135.
Kim RM,, Kahne DE,, Chapman KT, 2001, WO 0069-893, Chem Abstract 134, 5162.
136.
Kim SJ,, Cegelski L,, Strudelska DR,, O’Connor RD,, Mehta AK,, Schaefer J, 2002, The mode of action of vancomycin derivative LY 333328 characterized by redox, 42nd Intersci Conf Antimicrob Agents Chemother, abstract F-351.
137.
Kruszenska D,, Sahl H-G,, Bierbaum G,, Pag U,, Hynes SO,, Ljungh A, 2004, Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model, J Antimicrob Chemother, 54, 648– 653.
138.
Kubo I,, Xiao P,, Fujita K, 2002, Anti-MRSA activity of alkyl gallates, Bioorg Med Chem Lett, 12, 113– 116.
139.
Kumar V,, Kenia J,, Mukhopadyay T,, Nadakarm SR, 1999, Methylsulfomycin I, a new cyclic peptide antibiotic from Streptomyces sp HIL-Y 9420704, J Nat Prod, 62, 1562– 1564.
140.
Kusnick C,, Jansen R,, Liberra K,, Lindequist U, 2002, Ascochital, a new metabolite from the marine ascomycete Kirschsteiniothelia maritima, Pharmazie, 57, 510– 512.
141.
Lafland D,, Di, Funtorum S,, Waller A,, Clements JH,, Weaver MK,, Karlowsky JA,, Johnson K, 2004, In vitro antibacterial activity of the peptide deformylase inhibitor BB-83968, J Antimicrob Chemother, 53, 664– 666.
142.
Laub J,, Greenlee MC,, DiNinno F,, Hüber JL,, Sundelof JG, 1999, The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranoylcarbapenems, Bioorg Med Chem Lett, 9, 2973– 2976.
143.
Lambert A, 2002, Cellular impermeability and uptake of biocides and antibiotics in gram-positive bacteria and mycobacteria, J Appl Microbiol, 92, 46S– 54S.
144.
Lankas GR,, Coleman JB,, Klein HJ,, Bailly Y, 1996, Species specificity of 2-aryl carbapenem-induced immunemediated hemolytic anemia in primates, Toxicology, 108, 207– 215.
145.
Lee JS,, Cho YS,, Chang MH,, Koh HY,, Chung BY,, Pae AN, 2003, Synthesis and in vitro activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone antibacterial agents, Bioorg Med Chem Lett, 13, 4117– 4120.
146.
Leighton A,, Gottlieb AB,, Dorr MP,, Jakes D,, Masconi G,, Van Saders C,, Mroszczak EJ,, Campell KCM,, Kelly E, 2004, Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers, Antimicrob Agents Chemother, 48, 940– 945.
147.
Lewis JG,, Ategbu AE,, Chen T,, Kumar SA,, Patel DV,, Hacbarth CJ,, Asano R,, Wu C,, Wang W,, Yuan Z,, Trias J,, White RJ,, Gordeev MF, 2004a, Novel antimicrobial 7-methyl lincosamine, prolamide analogs, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-1388.
148.
Lewis JG,, Gu S,, Kumar SA,, Chen T,, O’Dowd H,, Patel DV,, Blais J,, Wu C,, Wang W,, Yuan Z,, Trias J,, White RJ,, Gordeev MF, 2004b, Novel antimicrobial 7-methyl lincosamine, pipecolamide analogs, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-1389.
149.
Li J,, Chen G,, Webster JM, 1997a, Nematophin, a novel antimicrobial substance produced by Xenorhabdus nematophilus (Enterobacteriaceae), Can J Microbiol, 43, 770– 773.
150.
Li J,, Chen G,, Webster JM, 1997b, Synthesis and anti-staphylococcal activity of nematophin and its analogs, Bioorg Med Chem Lett, 7, 1379– 1352.
151.
Li MKW,, Scheuer PJ, 1984, A guainolide pigment from a deep sea gorgonia, Tetrahedron Lett, 25, 2109– 2110.
152.
Liassine N,, Auckenthaler R,, Descombes MC,, Bes M,, Vandenesch T,, Etienne J, 2004, Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes, J Clin Microb, 42, 825– 828.
153.
Liehr S,, Hansen E,, Khorlin A,, Roberts C,, Keicher J,, Zhang W,, Nadherny J, et al, 2001, A new family of DNA targeting compounds have potent activity against vancomycin-resistant enterococci and methicillin-resistant S. aureus, 41st Intersci Conf Antimicrob Agents Chemother, abstract F-1699.
154.
Limburg E,, Beyer D,, Gahlmann R, 2002, S. aureus resistance to TAN 1057 is mediated by modification of the bacterial ribosome, 42nd Intersci Conf Antimicrob Agents Chemother, abstract F-2032.
155.
Locher HH,, Specklin JL,, Borner Y,, Brohammer S,, Schroeder S,, Sigwalt C,, Hubschwerlen C, 2002, Synthesis and antibacterial action of novel-quinolone-linked oxazolidinone, 42nd Intersci Conf Antimicrob Agents Chemother, abstract 1317.
156.
Look FC,, Vacin C,, Dias TM,, Ho S,, Tran TN,, Lee LL,, Wiesner C,, Fang F,, et al, 2004, The discovery of baryl acids and amides exhibiting antibacterial activity against gram-positive bacteria, Bioorg Med Chem Lett, 14, 1423– 1426.
157.
Lübbers T,, Angehrn P,, Gmünder H,, Herzig S,, Kulhanek J, 2000, Design, synthesis and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors, Bioorg Med Chem Lett, 10, 821– 826.
158.
Manning DD,, Xie D,, Duong TN,, Decornez HY,, Dorsey M,, Awrey DE,, Kaplan N,, Bardouniotis E,, Clarke T,, Berman J,, Pauls H, 2004, Structure guided design, synthesis and in vitro characterization of aqueous soluble inhibitors of bacterial fatty acid biosynthesis, 44th Intersci Conf Antimicrob Agents Chemother, abstract F-318.
159.
Margolis PS,, Hackbarth CJ,, Yong DC,, Wang W,, Chen D,, Yuan Z,, White R,, Trias J, 2000, Peptide deformylase in Staphylococcus aureus, resistance to inhibition is mediated by mutations in the formyl transferase gene, Antimicrob Agents Chemother, 44, 1825– 1831.
160.
Matsumoto M,, Tamaoka H,, Ishigawa H,, Kikuchi M, 1998, In vitro and in vivo antibacterial activity of OPC-20011, a novel parenteral broad spectrum 2-oxaisocephem antibiotic, Antimicrob Agents Chemother, 42, 2943– 2949.
161.
Matsumoto N,, Momose T,, Umekita M,, Kinoshita N,, Chino M,, Iinumura H,, Sawa T,, Hawada M,, Takeuchi T, 1999, Diperamycin, a new antimicrobial antibiotic produced by Streptomyces griseoaurantiacus MK 393AF2. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities, J Antibiot, 51, 1087– 1092.
162.
Mazmanian SK,, Thon-That H,, Su K,, Schneewind O, 2002, An iron-regulated sortase anchors a class surface proteins during S. aureus pathogenesis, PNAS, 99, 2293– 2298.
163.
McAtee JJ,, Castle SL,, Qing J,, Boger DL, 2002, Synthesis and evaluation of vancomycin and vancomycin aglycone analogues that bear modifications in the residue 3 asparagine, Bioorg Med Chem Lett, 12, 1319– 1322.
164.
McNaught JG, 1906, On the action of cold and lukewarm tea on Bacillus typhosus, J Royal Army Med Corps, 7, 372– 373.
165.
Miller RA,, Humphrey GR,, Lieberman DR,, Ceglia SS,, Kennedy DJ,, Grabowski EJJ,, Reider PJ, 2000, A practical and efficient preparation of the releasable naphthosultam side-chain of a novel anti-MRSA carbapenem, J Org Chem, 65, 1399– 1406.
166.
Miura S,, Iwasaki Y,, Tatsuta K, 1994, Anti-MRSA activity of 1-(4-chlorophenyl)-3-dichlorophenyl and 3-trichlorophenyl-2-(1-H-imidazol-1-yl)-2-propen-1-one derivative, J Antibiot, 47, 1171–1172.
167.
Moise PA,, Schentag JJ, 2000, Vancomycin treatment failures in S. aureus lower respiratory tract infections, Intern J Antimicrob Agents, 16, suppl 1, S31– S34.
168.
Moise-Brocker PA,, Sakoulas G,, Eliopoulos GM,, Schentag J,, Forrest A,, Moellering RC Jr, 2004, Accessory gene regulation group II polymorphism in methicillin-resistant S. aureus is predictive of failure of vancomycin therapy, Clin Infect Dis, 38, 1700– 1705.